Compositions for stabilizing and delivering proteins

Patent metadata

Field	Value
Publication number	US-10722468-B2
Application number	US-201515503891-A
Country	US
Kind code	B2
Filing date	Aug 14, 2015
Priority date	Aug 14, 2014
Publication date	Jul 28, 2020
Grant date	Jul 28, 2020

Abstract

Compositions for stabilizing and delivering proteins and/or other bioactive agents are disclosed. The bioactive agents are embedded or encapsulated in a crystalline matrix. Typically the bioactive agents are in the form of micro- or nanoparticles. The crystalline matrix confers enhanced stability to the agents embedded therein relative to other microparticulate or nanoparticulate bioactive agents. The carriers are especially useful for stabilizing bioactive macromolecules, such as proteins.

First claim

We claim:

1. A composition in a form suitable for oral administration, comprising a semi-crystalline solid matrix, wherein the composition is not a hydrogel, comprising:
microparticles, nanoparticles, or a combination thereof, comprising a bioactive agent and at least one biocompatible polymer, wherein the bioactive agent is a protein or peptide, and wherein the microparticles, nanoparticles, or a combination thereof is entrapped in the matrix, and
at least one semi-crystalline water soluble polymer, wherein the total amount of semi-crystalline water soluble polymer in the matrix is at least 65% by weight of the total mass of the matrix,
wherein the matrix is characterized by a melting point of at least 40° C., wherein the matrix dissolves in an aqueous media at pH 2.0 over a period of time greater than one hour.

2. The composition of claim 1 , wherein the semi-crystalline water soluble polymer is selected from the group consisting of polyalkylene glycols, poloxamers, polyvinyl alcohols, hydroxyalkyl celluloses, polysorbates, polyoxyethylene stearates, carrageenans, and alignates, or a mixture thereof.

3. The composition of claim 1 , further comprising an excipient selected from the group consisting of poly(vinyl pyrrolidone) (PVP), surfactants, sucrose, and glycine.

4. The composition of claim 1 , wherein the microparticles, nanoparticles, or a combination thereof have an average particle size in the range from 10 nm to 5 μm, as measured using the Coulter method.

5. The composition of claim 1 , wherein the biocompatible polymer is a bioerodible or bioadhesive polymer.

6. The composition of claim 1 , wherein the bioactive agent is a protein.

7. The composition of claim 1 , wherein the bioactive agent is selected from the group consisting of PDGF, SDF-1, VEGF, insulin, GM-CSF, IL-12, IL-10, GLP-1, IL-6R, IL-17, TNF-α, TGF-β1, infliximab, adalimumab, certolizumab, natalizumab, vedolizumab, J695, golimumab, CDP-870, AMG-181, nivolumab, secukinumab, and ustekinumab.

8. The composition of claim 1 , wherein the matrix further comprises an additional agent.

9. The composition of claim 1 , wherein the composition further comprises at least one diluent or vehicle.

10. The composition of claim 1 , wherein the composition is formulated such that after storage at 4° C. for 32 weeks, the release from the matrix of the bioactive agent into an aqueous solution is at least 30% of the amount of the bioactive agent released from a freshly prepared matrix.

11. The composition of claim 1 , wherein the composition is formulated such that after storage at 4° C. for 32 weeks, the bioactivity of the bioactive agent released from the matrix is at least 30% of the bioactivity of the bioactive agent released from a freshly prepared matrix.

12. A method of increasing the uptake of a bioactive agent at a site in the gastrointestinal tract of a patient in need of treatment, comprising orally administering to the patient a composition comprising a semi-crystalline solid matrix, wherein the composition is not a hydrogel, comprising:
microparticles, nanoparticles, or a combination thereof, comprising the bioactive agent and at least one biocompatible polymer, wherein the bioactive agent is a protein or peptide, and wherein the microparticles, nanoparticles, or a combination thereof are entrapped in the matrix, and at least one semi-crystalline water soluble polymer, wherein the total amount of semicrystalline water soluble polymer in the matrix at least 65% by weight of the total mass of the matrix,
wherein the matrix is characterized by a melting point of at least 40° C., wherein the microparticles, nanoparticles, or a combination thereof are selectively taken up at a site in the gastrointestinal tract, and
wherein the matrix dissolves in an aqueous media at pH 2.0 over a period of time greater than one hour.

13. The method of claim 12 , wherein the site in the gastrointestinal tract is Peyer's patches or gastrointestinal enterocytes.

14. The method of claim 12 , wherein the composition releases at least 30% of the bioactive agent in the intestines.

15. The method of claim 12 , wherein the patient in need of treatment has Crohn's disease, ulcerative colitis, irritable bowel syndrome, gastrointestinal cancer, or celiac disease.

16. The composition of claim 1 , wherein the biocompatible polymer is selected from the group consisting of polylactic acid, polyglycolic acid, poly(lactide-co-glycolide), poly(fumaric-co-sebacic anhydride), polycaprolactone, and blends or copolymers thereof.

17. The composition of claim 1 , wherein the matrix comprises more than one semi-crystalline water soluble polymer, wherein the more than one semi-crystalline water soluble polymer comprises polyethylene glycol and a poloxamer.

18. The composition of claim 1 , wherein the matrix further comprises a second biocompatible polymer selected from the group consisting of polylactic acid, polyglycolic acid, poly(lactide-co-glycolide), poly(fumaric-co-sebacic anhydride), polycaprolactone, and blends or copolymers thereof.

19. The composition of claim 1 , wherein the microparticles, nanoparticles or a combination thereof further comprise polyethylene glycol and a poloxamer.

Assignees

• Univ Brown
• Therapyx Inc

Inventors

• Mathiowitz Edith
• Furtado Stacia
• Egilmez Nejat
• Conway Thomas

Classifications

• A61K9/1635 Primary

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61K38/2066

  IL-10 · CPC title

• A61K38/191

  Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta · CPC title

• A61K38/20

  Interleukins [IL] · CPC title